Safety and immunogenicity of an MF59® -adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
Highlights ► Two doses of MF59-H5N1 vaccine were well tolerated. ► Two doses of MF59-H5N1 vaccine induced adequate levels of seroprotection against homologous and cross-clade A/H5N1 virus. ► These data support the suitability of MF59-adjuvanted A/H5N1 vaccine for pre-pandemic use in adults and the e...
Saved in:
Published in: | Vaccine Vol. 30; no. 7; pp. 1388 - 1396 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Netherlands
Elsevier Ltd
08-02-2012
Elsevier Limited |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Highlights ► Two doses of MF59-H5N1 vaccine were well tolerated. ► Two doses of MF59-H5N1 vaccine induced adequate levels of seroprotection against homologous and cross-clade A/H5N1 virus. ► These data support the suitability of MF59-adjuvanted A/H5N1 vaccine for pre-pandemic use in adults and the elderly. |
---|---|
Bibliography: | http://dx.doi.org/10.1016/j.vaccine.2011.12.009 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2011.12.009 |